Novo Nordisk (NVO) and Eli Lilly's (LLY) weight loss drugs lead Evaluate Pharma’s list of best-selling drugs projected for ...

Key Takeaways Novo Nordisk shares rose Wednesday on the company's home market in Denmark and in the U.S. after UBS analysts ...

At least four analysts weighed in on the prospects for Europe’s second-largest company, Novo Nordisk, after the Danish ...

Scope of collaboration originally signed in 2023 will significantly expand to enable the discovery and development of up to 20 novel drug programmes in obesity, type 2 diabetes, and cardiovascular dis ...

Collaboration leverages Variant Bio's innovative VB-Inference Platform and expertise partnering with global ...

Berenberg lowered the firm’s price target on Novo Nordisk (NVO) to DKK 725 from DKK 975 and keeps a Hold rating on the shares.Don't Miss Our ...

What happened with Novo Nordisk stock? On Dec. 20, Novo announced results from a phase 3 clinical trial surrounding one of ...

The general mood among these heavyweight investors is divided, with 50% leaning bullish and 31% bearish. Among these notable ...

Options trading presents higher risks and potential rewards. Astute traders manage these risks by continually educating ...

Amidst a race with its competitors to produce the next smash-hit weight loss drug, Novo Nordisk's (NYSE: NVO) stock crashed by 19% on Dec. 20, after the company reported results from a late-stage ...

Amidst a race with its competitors to produce the next smash-hit weight loss drug, Novo Nordisk's (NYSE: NVO) stock crashed by 19% on Dec. 20, after the company reported results from a late-stage ...

Shares of Novo Nordisk A/S (NVO) are trading sharply lower today as the company reported positive but underwhelming results from the phase 3 REDEFINE-1 trial of CagriSema in adult patients with ...